RLMD stock news
This page provides real-time market news, earnings updates, and company announcements related to Relmada Therapeutics, Inc. (RLMD).
All content is aggregated from trusted financial media and market data sources to help investors stay informed about key market movements and corporate developments.
Last updated as of 2026-03-12 03:01 EST
Relmada Therapeutics Reports 12-Month Phase 2 Interim Data for NDV-01 in Non-Muscle Invasive Bladder Cancer
Finviz2026-03-09 11:03:47
Relmada Therapeutics Announces Oversubscribed $160.0 Million Private Placement Financing
Finviz2026-03-09 11:09:55
Relmada Therapeutics recently announced positive data for its investigational drug NDV-01 in high-risk non-muscle invasive bladder cancer.
老虎证券2026-03-09 11:18:58
Relmada Therapeutics recently disclosed that its phase 3 second-line study targeting BCG non-responsive patient groups is expected to yield preliminary 3-month efficacy data by the end of 2026.
老虎证券2026-03-09 11:19:04
RLMD stock chart
RLMD stock detailsRLMD stock price change
On the last trading day, RLMD stock closed at 6.62 USD, with a price change of -7.67% for the day.
Trade stock perpsAbout Bitget
The world's first Universal Exchange (UEX), enabling users to trade not only cryptocurrencies, but also stocks, ETFs, forex, gold, and real-world assets (RWA).
Learn more